-+ 0.00%
-+ 0.00%
-+ 0.00%

PTC Therapeutics Executive VP and CLO Mark Elliott Boulding Reports Sale of $174,013.31 in Common Shares

PUBT·11/18/2026 22:20:55
Listen to the news
PTC Therapeutics Executive VP and CLO Mark Elliott Boulding Reports Sale of $174,013.31 in Common Shares
  • PTC Therapeutics executive vice president and CLO Mark Elliott Boulding sold 2,812 common shares on Nov. 16, 2026.
  • Sales comprised 1,315 shares at $61.39, 1,288 at $62.22 and 209 at $62.9.
  • Boulding also exercised stock options for 2,812 common shares at $25.69 per share on the same date.
  • Following the transactions, he directly owned 105,272 common shares and held 14,064 stock options.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001578852-26-000028), on November 18, 2026, and is solely responsible for the information contained therein.